India Business Revenue (FY26)
12,500 Cr
+15% YoY
India business crossed 12,500 Cr in FY26, growing 15% YoY in Q4.
CIPLA
Healthcare
30 Apr 2026
Cipla Ltd — Q4 FY26
Cipla delivered a strong Q4 FY26 with India business growing 15% YoY and North America revenue of $155M.
✓ Verified against BSE filing
2-Min Summary
✦ AI-Generated from Full Transcript
Cipla delivered a strong Q4 FY26 with India business growing 15% YoY and North America revenue of $155M. The company achieved key milestones including generic Ventolin approval and crossing 12,500 Cr in India revenue. Management guided for FY27 EBITDA margins of 18.5-20% with sequential improvement, driven by US respiratory launches and India chronic portfolio expansion. The US business targets a $1B run-rate by FY27-end, supported by 4 respiratory approvals and a peptide launch. Key risk: geopolitical disruptions and war-related cost inflation could pressure near-term margins.
Key Numbers
Albuterol Market Share
19.6%
Flat YoY
Albuterol market share stood at 19.6% as of March 2026, maintaining #1 position.
US Revenue (FY26)
$780M
+14% YoY
US business reported annual revenue of $780M, supported by differentiated portfolio.
Chronic Mix (India)
60%
+2pp YoY
Chronic mix improved to 60% as per IQVIA March 2026, driven by respiratory and cardiac.
Management Guidance
FY27 EBITDA margin guidance of 18.5-20%
Management expects EBITDA margins in the range of 18.5-20% for FY27, with sequential improvement and stronger H2.
Management guidance marginsUS business to reach $1B run-rate by FY27-end
Cipla targets a $1 billion annualized run-rate for US business by end of FY27, driven by respiratory and peptide launches.
Management guidance revenueIndia business to deliver double-digit growth in FY27-28
Management expects strong double-digit and market-beating growth in India for FY27 and FY28.
Management guidance growthR&D spend to remain around 7% of sales
R&D investment will continue at approximately 7% of revenue, supporting complex generics and biosimilars pipeline.
Management guidance otherKey Risks
Geopolitical disruption and war-related cost inflation
Ongoing geopolitical situation has started impacting operating expenses; if prolonged, could pressure margins.
medium · management_commentaryLanreotide supply disruption and remediation uncertainty
Lanreotide remains off market due to partner remediation; timeline for return is uncertain, with alternate supplier filing expected by Q4 FY27.
high · analyst_questionIndore facility regulatory overhang
Indore site still under regulatory scrutiny; while most filings shifted to US/Goa, any adverse outcome could delay future filings.
medium · analyst_questionExecution risk in US respiratory launches
Achieving $1B run-rate depends on timely approvals and commercial execution of 4 respiratory assets; any delay could impact guidance.
medium · data_observationNotable Quotes
We are expecting to launch this product within the coming months. Our Goa facility together with two US facilities is well equipped to support the launch of all four respiratory assets planned for FI27.
We expect the EBITDA margins to be in the range of 18.5% to 20%... this guidance does not include any contribution from lanreotide in FY27.
We are confident that we'll be able to deliver a strong double-digit growth as well as a market beating growth in FI27-28.
Frequently Asked Questions
What was Cipla's revenue in Q4 FY26?
Cipla reported revenue of ₹6,541 Cr in Q4 FY26, representing a — change compared to the same quarter last year.
What guidance did Cipla management give for FY27?
FY27 EBITDA margin guidance of 18.5-20%: Management expects EBITDA margins in the range of 18.5-20% for FY27, with sequential improvement and stronger H2. US business to reach $1B run-rate by FY27-end: Cipla targets a $1 billion annualized run-rate for US business by end of FY27, driven by respiratory and peptide launches. India business to deliver double-digit growth in FY27-28: Management expects strong double-digit and market-beating growth in India for FY27 and FY28. R&D spend to remain around 7% of sales: R&D investment will continue at approximately 7% of revenue, supporting complex generics and biosimilars pipeline.
What are the key risks for Cipla in FY27?
Key risks include Geopolitical disruption and war-related cost inflation — Ongoing geopolitical situation has started impacting operating expenses; if prolonged, could pressure margins.; Lanreotide supply disruption and remediation uncertainty — Lanreotide remains off market due to partner remediation; timeline for return is uncertain, with alternate supplier filing expected by Q4 FY27.; Indore facility regulatory overhang — Indore site still under regulatory scrutiny; while most filings shifted to US/Goa, any adverse outcome could delay future filings.; Execution risk in US respiratory launches — Achieving $1B run-rate depends on timely approvals and commercial execution of 4 respiratory assets; any delay could impact guidance..
Did Cipla meet its previous quarter's guidance?
Scorecard data is being built as historical quarters are processed.
Where can I read the full Cipla Q4 FY26 concall transcript?
The full earnings conference call transcript or source release is available on the linked source material. This page provides an AI-generated summary verified against official BSE/NSE filings.